SARS-CoV2 induced respiratory distress: Can cannabinoids be added to anti-viral therapies to reduce lung inflammation?

Byrareddy, Siddappa N; Mohan, Mahesh

Byrareddy, Siddappa N; Mohan, Mahesh.

Byrareddy SN; Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, United States. Electronic address: sid.byrareddy@unmc.edu.
Mohan M; Texas Biomedical Research Institute, Southwest National Primate Research Center, San Antonio, TX 78227, United States. Electronic address: mmohan@txbiomed.org.

Brain Behav Immun ; 87: 120-121, 2020 07.

Article in English | MEDLINE | ID: covidwho-133648

Subject(s)

COVID-19; Cannabinoids; Pneumonia; Respiratory Distress Syndrome; Cannabinoids/therapeutic use; Humans; Pneumonia/drug therapy; RNA, Viral; Respiratory Distress Syndrome/drug therapy; SARS-CoV-2

Keywords

Cannabinoids; Cytokine; Inflammation; Lung; Rhesus macaque; SARS-CoV2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia / Respiratory Distress Syndrome / Cannabinoids / COVID-19 Limits: Humans Language: English Journal: Brain Behav Immun Journal subject: Allergy and Immunology / Brain / Psychophysiology Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google